Company: EVGN
Filing Date: 2025-03-28
Form Type: POS AM
Source: 0001178913-25-001096
Chunk: 7

Company: Evogene Ltd.
Filing Date: 2025-03-28
Form: POS AM
Chunk 7
---
 technological engines to support the development of life science-based products through dedicated subsidiaries and with strategic partners. Currently, our main activities are directed through our subsidiaries, that utilize the technological engines to develop human microbiome-based therapeutics by Biomica, ag-chemicals by AgPlenus, ag-biologicals by Lavie Bio and castor seeds for bio-based industrial applications by Casterra. For additional information about our business, you should refer to our reports under the Exchange Act, referenced under the heading “Information Incorporated by Reference.” Before making an investment decision, you should read this entire prospectus, and our other filings with the SEC, including those filings incorporated herein and therein by reference, carefully, including the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”. Corporate Information Our registered office and principal place of business is located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel, and our telephone number in Israel is +972 (8) 931-1900. Our website address is http://www.evogene.com. We have included our website address in this prospectus supplement solely as an inactive textual reference. Our registered agent in the United States is Puglisi & Associates, whose address is 50 Library Avenue, Suite 204, Newark, Delaware 19711, United States. 2 THE OFFERING

| Ordinary shares outstanding as of the date of this prospectus |     | 6,672,173ordinary shares.                                                                                                                                                                                                                          |
| Ordinary shares offered by the Selling Shareholder            |     | 3,384,616 ordinary shares constituting the ordinary shares underlying the Series A warrants and the Series B warrants, or,                                                                                                                         
 together, the ordinary warrants, issued by us to the Selling Shareholder in an August 26, 2024 private placement.                                                                                                                                  
 Each ordinary warrant has an exercise price per share of $3.55 and was exercisable immediately upon issuance. The Series A                                                                                                                         
 warrants will expire on the five-year anniversary of the date of issuance (i.e., on August 26, 2029), while the Series B warrants will expire on the 18-month anniversary of the date of issuance (i.e., on February 26, 2026).                    |
| Ordinary shares to beoutstanding after this offering (1)      |     | 10,056,789 ordinary shares, assuming the exercise in full of all 3,384,616 of the